Ephedrine
Ephedrine produces modest weight loss (about 0.9 kg/month per Shekelle 2003 JAMA) and a real ergogenic boost (+39% time-to-exhaustion in Bell 1998) but carries a multi-pathway multi-pathway intrinsic life-threatening risk profile: sudden cardiac death, stroke, heatstroke, and hypertensive crisis with MAOIs are documented at therapeutic doses. The 2004 FDA dietary-supplement ban remains in force.
Ephedrine scored 4.2 / 10 (⚠️ Proceed with caution) on the BioHarmony scale as a Substance → Pharmaceutical / Drug.
What It Is
Ephedrine is a sympathomimetic alkaloid first isolated from ma huang (Ephedra sinica) in 1885. It produces direct alpha-1 and beta-1/2/3-adrenergic agonism plus indirect norepinephrine displacement, driving thermogenesis, bronchodilation, vasoconstriction, and central nervous system stimulation. Pharmaceutical ephedrine HCl remains FDA-approved as a behind-the-counter bronchodilator (Bronkaid) under the Combat Methamphetamine Epidemic Act controls; ephedrine sulfate IV is approved for hypotension during anesthesia.
The FDA ephedra ban under 21 CFR 119 under 21 CFR 119 removed ephedra-containing dietary supplements from the US market after more than 18,000 adverse event reports including cardiovascular events, stroke, and deaths. The pharmaceutical channel was unaffected. Modern off-label use centers on the ECA stack (ephedrine + caffeine + aspirin) for cutting protocols in bodybuilding, where the synergy produces approximately 0.9 kg/month additional weight loss above placebo per Shekelle 2003 JAMA meta-analysis of 20 RCTs.
The risk profile is the defining feature. Catastrophic events including sudden cardiac death, hemorrhagic and ischemic stroke, fatal myocardial infarction, fatal arrhythmia, heatstroke under exertion, and seizures are documented as intrinsic mechanisms at therapeutic doses, though Hallas 2008 Danish registry of 257,364 prescription users showed OR 0.95 for cardiovascular events under medical supervision. The catastrophic signal concentrates in unscreened supplement populations.
Terminology
- ECA stack: ephedrine + caffeine + aspirin (typically 25 mg + 200 mg + 81 mg three times daily); the canonical bodybuilding cutting protocol.
- Tachyphylaxis: rapid loss of response to a drug with continuous use; for ephedrine, driven by norepinephrine store depletion and beta-2 receptor desensitization within 2-4 weeks.
- MAOI: monoamine oxidase inhibitor (phenelzine, tranylcypromine, selegiline, linezolid); absolute contraindication for ephedrine due to hypertensive crisis risk at any dose.
- the Combat Methamphetamine Epidemic Act: Combat Methamphetamine Epidemic Act; federal law requiring photo ID, NPLEx logbook signature, and monthly purchase limits for ephedrine and pseudoephedrine.
- NPLEx: National Precursor Log Exchange; the federal database tracking ephedrine and pseudoephedrine purchases at the pharmacy counter.
- WADA: World Anti-Doping Agency; ephedrine prohibited in-competition above 10 mcg/mL urine concentration.
- Bronkaid: Bayer brand name for OTC ephedrine sulfate 25 mg + guaifenesin 400 mg behind-the-counter bronchodilator product.
- Ma huang: Ephedra sinica, the Traditional Chinese Medicine herb from which ephedrine was first isolated in 1885.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 2 routes and 3 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral (tablet) | Ephedrine HCl 8 mg, ephedrine sulfate 25 mg | Bronchodilation: 12.5-25 mg every 4 hours; weight loss (RCT context): 20-25 mg three times daily; FDA bronchodilator label max 150 mg/day | ECA stack: 25 mg three times daily (75 mg/day); experienced users 50-100 mg/day; outlier dosing 150-240 mg/day reported with severe AEs |
| Intravenous (anesthesia setting) | Ephedrine sulfate injectable 50 mg/mL | 5-25 mg IV bolus for hypotension during spinal/epidural anesthesia | Not applicable. Hospital use only. |
Protocols
ECA stack (cutting / weight loss) Anecdotal
- Dose
- 25 mg ephedrine + 200 mg caffeine + optional 81 mg aspirin, three times daily
- Frequency
- TID with breakfast, lunch, mid-afternoon (last dose by 2 PM)
- Duration
- 4-8 weeks on, 2-4 weeks off; do not exceed 3 cycles per year
Boozer 2002 6-month RCT used herbal ephedra/caffeine 90/192 mg/day with -5.3 kg vs -2.6 kg placebo result. Modern community uses synthetic ephedrine HCl tablets.
Bronchodilator (asthma, historical) Clinical
- Dose
- 12.5-25 mg every 4 hours as needed
- Frequency
- PRN for acute bronchospasm
- Duration
- Acute use only; maintenance asthma therapy obsolete since beta-2 selective inhalers
Largely supplanted by albuterol and other beta-2 selective bronchodilators with better cardiac safety profile.
IV anesthesia hypotension Clinical
- Dose
- 5-25 mg IV bolus, repeat as needed
- Frequency
- Single or repeat boluses during anesthesia
- Duration
- Single procedure
Standard pressor for spinal/epidural-induced hypotension. Largest modern body of controlled human cardiovascular data.
How this score is calculated →
Upside contribution: 2.83
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.8 | 0.700 | |
| Breadth of Benefits | 15% | 3.5 | 0.525 | |
| Evidence Quality | 25% | 3.0 | 0.750 | |
| Speed of Onset | 10% | 4.0 | 0.400 | |
| Durability | 10% | 1.5 | 0.150 | |
| Bioindividuality Upside | 15% | 2.0 | 0.300 | |
| Total | 2.825 |
Upside Rationale
Ephedrine has real upside when the use case matches its best evidence, especially around body composition, energy, respiratory, endurance cardio. Shekelle 2003 and Shekelle 2003 support the main positive signal, but the useful part is not the headline mechanism. It is the chance to connect Ephedrine to a measurable outcome and see whether the expected change appears. The upside is strongest for users with the relevant baseline problem, weaker for optimized users chasing a vague edge, and most honest when paired with tracking. For this report, Ephedrine earns credit for plausible mechanisms, human or clinical anchors where available, and practical fit. The right read is targeted use, not automatic daily inclusion.
Efficacy (2.8/5.0). The benefit case is real but modest. Shekelle 2003 JAMA meta-analysis of 20 RCTs found 0.9 kg/month above placebo for ephedra/caffeine combinations. Boozer 2002 6-month RCT (n=167) showed -5.3 vs -2.6 kg with herbal ephedra/caffeine. Cho 2024 updated meta of 16 RCTs (n=1,460) confirmed MD -1.5 kg, but all included studies were rated some-concerns or high risk of bias. Athletic performance benefit confirmed: Bell 1998 +39% time-to-exhaustion. The 2026 alternative landscape is unfavorable: GLP-1 agonists deliver 5-15% body weight reduction with cleaner safety profiles, reducing the relative attractiveness of ephedrine for body composition.
Breadth of benefits (3.5/5.0). Multi-system action via sympathetic activation: weight loss, thermogenesis, bronchodilation, central stimulation, and appetite suppression. The pharmacology touches respiratory, metabolic, cardiovascular, and CNS systems. Historical asthma indication via beta-2 bronchodilation, modern weight-loss use via thermogenesis plus appetite suppression, and acute pressor use in anesthesia all share the same molecule. Score sits below 4.0 because most non-weight-loss applications have safer alternatives (albuterol for asthma, modafinil for cognition, phenylephrine for nasal congestion).
Evidence quality (3.0/5.0). Substantial RCT base with Shekelle 2003 JAMA and updated meta-analyses through 2024. However, no Cochrane review exists, all 16 trials in Cho 2024 were rated some-concerns or high risk of bias, industry funding concentrated heavily during the supplement era, and Metabolife concealed adverse event reports per discovery in MDL litigation. The pharmaceutical evidence base (Hallas 2008 registry) is more independent but smaller. A 0.5-point weighting adjustment applies to the supplement-era trial portfolio.
Speed of onset (4.0/5.0). Tmax 1.8 hours oral; thermogenic effect within 30-60 minutes; subjective stimulation within 30 minutes; peak ergogenic benefit at 1-2 hours per Bell 1998 timing. Weight loss measurable within 4-12 weeks. Faster onset than most pharmaceutical interventions but not trivial like caffeine alone.
Durability (1.5/5.0). Tachyphylaxis develops within 2-4 weeks of continuous use, driven by norepinephrine store depletion (recovers in 24-48 hours of cessation) and beta-2 adrenergic receptor desensitization (recovers in days to weeks). Community cycling protocols mandate 4-8 weeks on followed by 2-4 weeks off. Effects fade rapidly on cessation. Weight regain typical within 6-12 months of stopping, though Boozer 2002 did not include extended follow-up. The intervention is functionally an acute pharmacological tool rather than a durable lifestyle modifier.
Bioindividuality (2.0/5.0). Extensive contraindications narrow the addressable population dramatically. Absolute contraindications: MAOI users, pre-existing CAD or arrhythmia, uncontrolled hypertension, hyperthyroidism, BPH, narrow-angle glaucoma, seizure disorders, pregnancy and lactation, age under 12. Strong cautions: anxiety disorders, T2DM, athletes in heat-stress contexts, elderly. Pharmacogenomics: CYP2D6 poor metabolizers clear ephedrine slower; beta-3 Trp64Arg variants (more common East Asian populations) blunt thermogenic response. The intervention works for approximately 40-50% of an unscreened general population, but the contraindication overlay narrows the safe-and-effective addressable group considerably.
Downside contribution: 4.02 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 4.0 | 1.200 | |
| Side Effect Profile | 15% | 3.5 | 0.525 | |
| Financial Cost | 5% | 1.5 | 0.075 | |
| Time/Effort Burden | 5% | 2.5 | 0.125 | |
| Opportunity Cost | 5% | 3.5 | 0.175 | |
| Dependency / Withdrawal | 15% | 2.5 | 0.375 | |
| Reversibility | 25% | 2.0 | 0.500 | |
| Total | 2.975 | |||
| Harm subtotal × 1.4 | 3.640 | |||
| Opportunity subtotal × 1.0 | 0.375 | |||
| Combined downside | 4.015 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 2.675 |
Downside Rationale
Safety risk (4.0/5.0). The worst-case safety risk is severe and intrinsic to the molecule. Multiple distinct intrinsic catastrophic mechanisms documented at therapeutic doses: sudden cardiac death from sympathomimetic cardiac stimulation; hemorrhagic stroke from pressor-mediated cerebrovascular rupture (mechanism documented in the closely-related PPA evidence by Kernan 2000 with women using appetite suppressants showing OR 16.58, 95% CI 1.51-182.21); fatal MI from coronary vasospasm; fatal arrhythmia from QT prolongation and afterdepolarizations; heatstroke under exertion from thermogenic plus impaired thermoregulation (the Bechler heatstroke mechanism); and seizures from CNS sympathetic overload. Haller and Benowitz 2000 NEJM review of 140 FDA MedWatch cases documented 47% cardiovascular events, 10 deaths, 13 permanent disabilities. The 4.0 floor reflects multiple distinct intrinsic catastrophic clusters rather than stacking from a single AE pattern. MAOI hypertensive crisis is interaction-mediated and not stacked into the floor per scoring methodology.
Side effect profile (3.5/5.0). Frequent and disruptive. Shekelle 2003 reported 2.2-3.6x increased odds of psychiatric (anxiety, irritability, insomnia), autonomic (palpitations, tremor, sweating), and gastrointestinal (nausea, dry mouth, heartburn) symptoms vs placebo. Community reports confirm 30-50% of new users experience anxiety or palpitations at 25 mg single doses. Insomnia from late-day dosing is near-universal, requiring 2 PM cutoff discipline. Sleep architecture disruption compounds over multi-week cycles. Heart rate elevation per Yoo 2021 +5.76 bpm sustained.
Financial cost (1.5/5.0). Bronkaid behind-the-counter ephedrine sulfate ~$0.50 per tablet; ECA stack ~$0.50-1.00 per day; ephedrine HCl 8 mg generics under $0.10 per tablet. Cost is among the lowest of any pharmaceutical intervention. The cost barrier is access friction (the Combat Methamphetamine Epidemic Act controls, pharmacist discretion) rather than dollars.
Time / effort burden (2.5/5.0). Real protocol overhead beyond a simple daily supplement. Behind-the-pharmacy-counter access per the Combat Methamphetamine Epidemic Act: every purchase requires photo ID, signing the federal NPLEx logbook, and pharmacist discretion (which varies by state and individual pharmacy; community threads document refusals when bodybuilding is volunteered as the purpose). Monthly purchase limits force re-purchase scheduling and may require pharmacy rotation for heavy users. Cycling discipline (4-8 weeks on, 2-4 weeks off) requires actual protocol management. Two-to-three times daily dosing schedule with mandatory cutoff before mid-afternoon to avoid insomnia. Asthma, glaucoma, BPH, hyperthyroid, MAOI, and SSRI screening required for self-administering users. Total daily effort overhead is modest at approximately 5 minutes, but the access friction plus cycling discipline plus drug-interaction-awareness load lifts this above a true zero-effort intervention.
Opportunity cost (3.5/5.0). Significantly better alternatives exist for every primary use case. For body composition: GLP-1 agonists (semaglutide, tirzepatide) deliver 5-15% body weight reduction with cleaner safety profile and explicit cardiovascular safety data. For athletic performance: caffeine alone, beta-alanine, creatine all deliver portion of the benefit without adrenergic crisis risk. For asthma: beta-2 selective inhalers (albuterol, salmeterol) deliver superior bronchodilation with vastly better cardiac safety. For energy: structured sleep, caffeine, modafinil, L-tyrosine all carry lower CV cost. The intervention's opportunity cost is high precisely because the alternatives are so good.
Dependency / withdrawal (2.5/5.0). Tachyphylaxis (receptor downregulation and norepinephrine depletion) is the dominant pattern, not addiction in the dopaminergic-craving sense. Stopping after 4-8 weeks of use produces fatigue, depression, and irritability for several days as catecholamine systems renormalize, but no compulsive use signal in the dependency literature. Heavy users at 100+ mg/day report more pronounced crash patterns suggesting cumulative HPA-axis dysregulation. Functional dependency to maintain thermogenic effect during cutting cycles, but cessation is not pharmacologically blocked.
Reversibility (2.0/5.0). Mostly reversible: serum ephedrine clears within 24 hours of last dose; beta-2 receptor sensitivity recovers in days to weeks; weight regain typical within 6-12 months without continued lifestyle support. However, contraction band necrosis on cardiac biopsy in chronic athlete users (per pathology literature) creates permanent arrhythmia substrate, raising long-term cardiac vulnerability that does not reverse. Heat-stress events that cause heatstroke can produce permanent renal, hepatic, or neurological damage. The intervention is reversible at the pharmacological level but can leave permanent damage from acute adverse events.
Verdict
Ephedrine is a 4.2/10 fit for people considering body composition, energy, respiratory, endurance cardio, with the strongest case in the populations already represented by the evidence rather than broad wellness use. Shekelle 2003 and Shekelle 2003 give the report its main anchors, while the score stays caution because benefits are context-dependent and the evidence still leaves responder, dose, and long-term questions open. Ephedrine makes the most sense when the target is concrete, such as a lab marker, symptom pattern, training limitation, or recovery bottleneck. It makes less sense as a background habit taken on faith. In practice, treat Ephedrine as a tracked experiment: define the outcome first, watch for tradeoffs, and let the response decide whether it earns a place.
✅ Best for: Time-bound (4-8 week) cutting protocols in screened adults without cardiovascular risk factors, MAOI/SSRI/TCA exposure, hyperthyroidism, BPH, narrow-angle glaucoma, seizure history, or pregnancy. Pharmaceutical-grade ephedrine HCl behind the pharmacy counter, never gray-market herbal ephedra. Anesthesiologists using ephedrine sulfate IV for spinal-anesthesia hypotension under medical supervision. Adults with mild bronchospasm without access to beta-2 selective inhalers. The narrow indication window is deliberate.
❌ Avoid if: You have any history of coronary artery disease, arrhythmia, hypertension, stroke, heart failure, or cardiomyopathy. You take MAOIs (absolute contraindication), SSRIs, SNRIs, TCAs, beta-blockers, halothane anesthesia, theophylline, or linezolid. You have hyperthyroidism, pheochromocytoma, BPH, narrow-angle glaucoma, diabetes with autonomic neuropathy, anxiety disorder, panic disorder, or a seizure history. You are pregnant or breastfeeding. You exercise in heat above 80°F. You are over 65 or under 18. You have a history of substance use disorder. You can access GLP-1 agonists, modafinil, or beta-2 inhalers as alternatives for the indication you were considering ephedrine for.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Body Composition / Fat Loss: 6.0/10
Score: 6.0/10Modest weight loss confirmed: Shekelle 2003 JAMA pooled 0.9 kg/month above placebo across 20 trials; Boozer 2002 6-month RCT showed -5.3 vs -2.6 kg with herbal ephedra/caffeine 90/192 mg/day. Cho 2024 MD -1.5 kg across 16 RCTs (n=1,460), all rated some-concerns or high risk of bias. GLP-1 agonists deliver 5-15% body weight reduction with cleaner safety profile.
Energy / Fatigue: 7.0/10
Score: 7.0/10Ephedrine earns 7.0/10 for energy; this is a targeted fit score. Reliable acute stimulation via direct + indirect adrenergic activation; Tmax 1.8 hours, peak effect 1-2 hours. Tachyphylaxis develops within 2-4 weeks of continuous use. Caffeine + L-tyrosine + adequate sleep produce comparable subjective energy without the cardiovascular cost. Carey 2015 Diabetologia showed chronic use suppresses brown adipose tissue activity by approximately 22% over 28 days. That makes Ephedrine more defensible when energy is a real bottleneck and less compelling when basics already cover the same ground.
Respiratory: 6.0/10
Score: 6.0/10For respiratory, Ephedrine lands at 6.0/10 because context matters. Historical asthma indication via beta-2 bronchodilation; largely supplanted since the 1980s by beta-2 selective inhalers (albuterol, salmeterol) with vastly better cardiac safety. Bronkaid (25 mg ephedrine sulfate + 400 mg guaifenesin) remains an OTC option for adults with mild bronchospasm without alternatives, but the the old FDA monograph restricted indication to symptomatic relief, not maintenance therapy. That makes Ephedrine more defensible when respiratory is a real bottleneck and less compelling when basics already cover the same ground.
Endurance / Cardio: 5.0/10
Score: 5.0/10Ephedrine gets 5.0/10 for endurance cardio; the evidence supports a narrow read. Bell 1998 showed caffeine + ephedrine improved time-to-exhaustion by 39% (17.5 vs 12.6 min) in 8 trained males at 5 mg/kg + 1 mg/kg. Bell 2000 lower-dose follow-up preserved approximately 60-66% improvement. Bell and Jacobs 1999 Warrior Test showed 3.3-4% run-time improvement. WADA bans in-competition above 10 mcg/mL urine threshold.
Cognition / Focus: 5.0/10
Score: 5.0/10The cognition focus score is 5.0/10, and Ephedrine needs careful framing. Adrenergic-driven alertness and reaction time benefit at acute doses; Sidney and Lefcoe 1977 found no benefit on reaction time, hand-eye coordination, or cognitive measures from a single 24 mg dose in 21 healthy males. Modafinil delivers more reliable cognitive enhancement with cleaner safety profile and explicit CV-safety data. That makes Ephedrine more defensible when cognition focus is a real bottleneck and less compelling when basics already cover the same ground.
Metabolic Health: 5.0/10
Score: 5.0/10Modest fat loss preserves lean mass: Astrup 1992 Metabolism showed 4.5 kg additional fat loss with 2.8 kg less FFM loss vs placebo over 8 weeks in 14 obese women on E+C 20/200 mg TID. Cardiometabolic profile in Yoo 2021 showed favorable HDL +2.74 mg/dL and LDL -5.98 mg/dL but heart rate +5.76 bpm and blood pressure increases that offset the lipid signal in CV-risk patients.
Strength / Power: 5.0/10
Score: 5.0/10For readers prioritizing strength power, Ephedrine scores 5.0/10 today. Jacobs 2003 resistance training study (n=13 males) showed first-set leg press reps improved from 13 to 19 with caffeine plus ephedrine, but effect diminished in subsequent sets. Useful for acute single-effort attempts; not for training periodization. Banned by WADA in competition. That makes Ephedrine more defensible when strength power is a real bottleneck and less compelling when basics already cover the same ground.
| Use Case | Score | Summary |
|---|---|---|
| ○ Mood / Emotional Regulation | 3.6 | Acute alertness and mood elevation reported anecdotally; chronic use associated with anxiety, irritability, panic, and insomnia per Shekelle 2003 which showed 2.2-3.6x increased odds of psychiatric, autonomic, and GI symptoms. Not a recommended mood intervention given the side effect profile. |
| ○ Recovery / Repair | 3.0 | No documented recovery benefit. Ephedrine increases sympathetic tone and may impair parasympathetic recovery, blunt sleep-driven repair processes, and elevate cortisol. Jacobs 2003 showed first-set leg press benefit (19 vs 13 reps) but no cumulative across-set benefit, suggesting acute potentiation does not translate to training adaptation. |
Frequently Asked Questions
Is ephedrine safe to take?
Pharmaceutical ephedrine under medical supervision shows minimal cardiovascular risk per Hallas et al. 2008, a Danish registry study of 257,364 prescription users with adjusted OR 0.95 (95% CI 0.79-1.16) for serious cardiovascular events. Dietary supplement use, however, produced 47% cardiovascular events with 10 deaths in Haller and Benowitz 2000 NEJM review of 140 FDA MedWatch reports. The FDA ephedra ban under 21 CFR 119 on ephedra-containing supplements (21 CFR 119) reflects that population-level supplement-context harm. Catastrophic risks are intrinsic at therapeutic doses: sudden cardiac death, stroke, fatal arrhythmia, heatstroke, and seizures all documented.
What is the difference between ephedrine and pseudoephedrine?
Ephedrine and pseudoephedrine are stereoisomers with similar adrenergic mechanisms but different receptor affinity profiles. Ephedrine has stronger bronchodilator and CNS stimulant activity; pseudoephedrine is more selective for nasal decongestion via alpha-1 vasoconstriction. Both are regulated under the Combat Methamphetamine Epidemic Act with photo ID + NPLEx logbook + monthly purchase limits. Ephedrine appears in cutting protocols at 25 mg three times daily; pseudoephedrine is sometimes substituted but produces less thermogenic effect. Athletic doping thresholds differ: ephedrine prohibited above 10 mcg/mL urine in-competition, pseudoephedrine above 150 mcg/mL.
Why was ephedra banned by the FDA?
The FDA banned ephedra-containing dietary supplements under the FDA April action under 21 CFR 119, citing more than 18,000 adverse event reports including cardiovascular events, stroke, and deaths. The decision was driven by Shekelle et al. 2003 JAMA meta-analysis which identified 'sentinel events' (death, MI, stroke, seizure) at a strong signal below conventional proof thresholds, the high-profile death of MLB pitcher Steve Bechler, and an American Heart Association petition. Pharmaceutical ephedrine HCl behind-the-counter and IV ephedrine sulfate for anesthesia were not affected by the supplement ban.
Can ephedrine actually help with weight loss?
Yes but modestly. Shekelle 2003 JAMA pooled 20 trials and found 0.9 kg/month additional weight loss above placebo. Boozer 2002 6-month RCT (n=167) showed -5.3 vs -2.6 kg on herbal ephedra/caffeine 90/192 mg/day. Cho 2024 meta-analysis of 16 RCTs (n=1,460) confirmed MD -1.5 kg, though all studies were rated some-concerns or high risk of bias. For comparison, GLP-1 agonists like semaglutide and tirzepatide produce 5-15% body weight reduction in trials with cleaner safety profiles, making the ephedrine risk-reward unfavorable for most users today.
What drugs interact dangerously with ephedrine?
MAOIs (phenelzine, tranylcypromine, selegiline, linezolid) are an absolute contraindication. Co-administration produces hypertensive crisis at any ephedrine dose due to MAO-mediated tyramine accumulation per the Boyer NEJM serotonin-syndrome review. SSRIs and SNRIs raise theoretical serotonin syndrome risk via indirect serotonin release. Beta-blockers produce unopposed alpha agonism and hypertensive crisis. Halothane anesthesia produces ventricular fibrillation. Theophylline produces additive cardiac toxicity. TCAs produce additive cardiotoxicity. Always screen the medication list before any ephedrine use.
Does ephedrine work for athletic performance?
Yes, with caveats. Bell et al. 1998 showed caffeine + ephedrine (5 mg/kg + 1 mg/kg) improved time-to-exhaustion by 39% (17.5 vs 12.6 min) in 8 trained males. Bell et al. 2000 lower-dose follow-up preserved approximately 60-66% improvement. Bell and Jacobs 1999 Warrior Test showed 3.3-4% run-time improvement. Jacobs et al. 2003 resistance training first-set leg press benefit (19 vs 13 reps) diminished across subsequent sets. WADA prohibits ephedrine in-competition above 10 mcg/mL urine. Sympathetic activation is the proximal mechanism, with thermoregulation impairment a documented adverse pathway under exertion in heat.
What does tachyphylaxis mean for ephedrine cycling?
Tachyphylaxis is the rapid loss of response with continuous use, driven primarily by norepinephrine store depletion (recovers in 24-48 hours of cessation) and beta-2 adrenergic receptor desensitization (recovers in days to weeks). Community cycling protocols typically run 4-8 weeks on followed by 2-4 weeks off, though Examine.com notes that the thermogenic fat-burning effect itself does not require cycling, only the CNS stimulation and appetite suppression. Heavy users at 100+ mg/day report crash patterns (fatigue, depression, irritability) on cessation, suggesting cumulative HPA-axis dysregulation beyond simple receptor downregulation.
What is ma huang and how does it relate to ephedrine?
Ma huang (麻黄, Ephedra sinica) is the Traditional Chinese Medicine herb from which ephedrine was first isolated by Nagai Nagayoshi at the University of Tokyo in 1885. Ma huang appears in the foundational Han-dynasty pharmacopoeia Shen Nong Ben Cao Jing (神農本草經), compiled approximately 200 BCE to 200 CE, and in Zhang Zhongjing's Mahuang Tang formula from the Shang Han Lun (傷寒論) approximately 200 CE for wind-cold respiratory presentations. The Chinese Pharmacopoeia classifies ma huang as a restricted-use herb requiring qualified prescriber dispensing. The 2,000-year traditional record consistently emphasizes short-term acute use under prescriber supervision, which aligns with the modern pharmaceutical safety record.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| New independent supervised pharmaceutical RCT replicates the Hallas Danish-registry null CV finding | Safety 4.0 to 3.5, Evidence 3.0 to 3.5 | 4.9 / 10 ⚖️ Neutral |
| FDA reverses 2004 ban allowing supervised ephedra supplementation | Effort 2.5 to 1.8, Cost 1.5 to 1.2 | 4.5 / 10 ⚖️ Neutral |
| GLP-1 agonist long-term (5+ year) CV safety confirmed superior | Opportunity 3.5 to 4.5 | 4.0 / 10 ⚠️ Caution |
| Pharmacogenomic test reliably identifies safe responders (CYP2D6 + beta-3 + cardiac risk) | Bioindiv 2.0 to 3.5, Safety 4.0 to 3.0 | 5.2 / 10 👍 Worth trying |
| Modern RCT documents permanent cardiac substrate in chronic users | Reversibility 2.0 to 1.0, Safety 4.0 to 4.5 | 3.9 / 10 ⚠️ Caution |
Key Evidence Sources
- Shekelle PG et al. 2003 - Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis, JAMA. 20 weight-loss RCTs; 0.9 kg/month above placebo; AE odds 2.2-3.6x
- Shekelle PG et al. 2003 - Ephedra and Ephedrine for Weight Loss and Athletic Performance: AHRQ Evidence Report. Full RAND/AHRQ report; 1,173 AERs analyzed; 69 deaths
- Yoo HJ et al. 2021 - Effects of Ephedrine-Containing Products on Weight Loss and Lipid Profiles, Pharmaceuticals. 10 RCTs; n=534; MD -1.97 kg
- Cho H et al. 2024 - Efficacy and safety of ephedra-containing oral medications, Frontiers in Pharmacology. 16 RCTs; n=1,460; MD -1.5 kg; all studies high risk of bias
- Boozer CN et al. 2002 - Herbal ephedra/caffeine for weight loss: a 6-month randomized trial, Int J Obes. Longest prospective RCT; n=167; -5.3 vs -2.6 kg
- Daly PA, Krieger DR et al. 1993 - Ephedrine, caffeine and aspirin: ECA safety and efficacy, Int J Obes. Original ECA stack human trial; n=24; 8 weeks
- Astrup A et al. 1992 - Ephedrine/caffeine on energy expenditure, Metabolism. n=14 obese women; 8 weeks; 4.5 kg additional fat loss
- Astrup A et al. 1992 - Ephedrine/caffeine compound vs placebo, Int J Obes. n=180; 24 weeks; 16.6 vs 13.2 kg weight loss with hypocaloric diet
- Haller CA, Benowitz NL 2000 - Adverse cardiovascular and CNS events from ephedra supplements, NEJM. 140 FDA MedWatch cases; 47% CV; 10 deaths; 13 disabilities
- Kernan WN et al. 2000 - Phenylpropanolamine and hemorrhagic stroke risk, NEJM. PPA case-control (not ephedrine); women appetite-suppressant OR 16.58 (CI 1.51-182.21); regulatory class context
- Hallas J et al. 2008 - Ephedrine/caffeine and cardiovascular risk, Am J Epidemiol. Danish registry n=257,364 prescription users; OR 0.95; medical supervision
- Carey AL et al. 2015 - Chronic ephedrine suppresses brown adipose tissue, Diabetologia. n=23 men; 28 days; BAT activity decline 22%
- Bell DG, Jacobs I, Zamecnik J 1998 - Caffeine, ephedrine and time to exhaustion, Eur J Appl Physiol. n=8 males; +39% time to exhaustion with C+E
- Bell DG, Jacobs I, McLellan TM, Zamecnik J 2000 - Reducing the dose of caffeine and ephedrine, Aviat Space Environ Med. Lower-dose follow-up; +60-66% preserved
- Jacobs I et al. 2003 - Ephedrine, caffeine on muscular endurance, Med Sci Sports Exerc. n=13 males; resistance training; first-set benefit only
- Boyer EW, Shannon M 2005 - The serotonin syndrome, NEJM. Serotonin syndrome mechanism; SSRI/SNRI interaction context
- Greenway FL 2001 - Pharmaceutical and herbal caffeine and ephedrine for weight loss, Obes Rev. Review; primary data sourced from Daly 1993
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: High
Citations: Shekelle 2003, Boozer 2002, Haller 2000, Hallas 2008, Cho 2024, Carey 2015
Pre-RCT-Era Pharmacology and Use
Confidence: High
Citations: Nagai 1885, Chen 1924
Traditional Medicine Systems
Confidence: High
Citations: Chinese 2020
Holistic Evidence for Ephedrine
All three lenses converge on a critical pattern: ephedrine works pharmacologically as a sympathomimetic, but unsupervised chronic use carries unacceptable cardiovascular risk. Traditional Chinese Medicine prescribed ma huang short-term for acute wind-cold presentations under qualified supervision. Western pharmacology used it as the standard asthma bronchodilator until safer beta-2 selectives replaced it. The Hallas 2008 Danish registry of pharmaceutically supervised users found minimal CV risk, while Haller and Benowitz 2000 found catastrophic events in unscreened supplement users. The honest synthesis: this is a supervised-use intervention with a narrow indication window, not a self-administered chronic supplement. The FDA ephedra ban under 21 CFR 119 codified that distinction.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Fasting Glucose Baseline (pre-protocol) During | Expected Up
- Cortisol AM During | Expected Up
- ALT During | Expected Stable
Pulse Dimensions to Watch
- Energy During | Expected Up | Primary
- Drive During | Expected Up | Primary
- Calm During | Expected Down | Secondary
Subjective Signals (Daily Voice Card)
- Jitters Scale 1-5 | During | Expected Up
- Appetite Scale 1-5 | During | Expected Down
- Sleep Disruption Scale 1-5 | During | Expected Up
Red Flags: Stop and Consult
- Chest pain, palpitations, or fainting
- Severe anxiety or panic
- Resting HR more than 15 bpm above baseline
Other interventions for Body Composition
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.825 − 2.675 = -0.850
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (-0.850 / 7) × 5 = 4.4 / 10
